The University of Chicago Header Logo

Connection

Mei-Yin Polley to Humans

Back to Details
This is a "connection" page, showing publications Mei-Yin Polley has written about Humans.
Mei-Yin Polley
Connection Strength
0.493
Humans
  1. Molecular Profiling in Neuro-Oncology: Where We Are, Where We're Heading, and How We Ensure Everyone Can Come Along. Am Soc Clin Oncol Educ Book. 2023 May; 43:e389322.
    View in: PubMed
    Score: 0.030
  2. On the Quest of Risk Stratification in HER2-Positive Breast Cancer. J Natl Cancer Inst. 2022 03 08; 114(3):345-346.
    View in: PubMed
    Score: 0.028
  3. A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. Breast Cancer Res Treat. 2021 Aug; 189(1):15-23.
    View in: PubMed
    Score: 0.027
  4. Statistical Considerations in the Evaluation of Continuous Biomarkers. J Nucl Med. 2021 05 10; 62(5):605-611.
    View in: PubMed
    Score: 0.026
  5. A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. Breast Cancer Res Treat. 2021 Feb; 185(3):557-566.
    View in: PubMed
    Score: 0.026
  6. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. 2020 06 18; 135(25):2224-2234.
    View in: PubMed
    Score: 0.025
  7. Power estimation in biomarker studies where events are already observed. Clin Trials. 2017 Dec; 14(6):621-628.
    View in: PubMed
    Score: 0.020
  8. An international study to increase concordance in Ki67 scoring. Mod Pathol. 2015 Jun; 28(6):778-86.
    View in: PubMed
    Score: 0.017
  9. Two-stage adaptive cutoff design for building and validating a prognostic biomarker signature. Stat Med. 2014 Dec 20; 33(29):5097-110.
    View in: PubMed
    Score: 0.017
  10. Statistical and practical considerations for clinical evaluation of predictive biomarkers. J Natl Cancer Inst. 2013 Nov 20; 105(22):1677-83.
    View in: PubMed
    Score: 0.016
  11. Development of omics-based clinical tests for prognosis and therapy selection: the challenge of achieving statistical robustness and clinical utility. Clin Trials. 2013 Oct; 10(5):653-65.
    View in: PubMed
    Score: 0.016
  12. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 01; 29(31):4175-80.
    View in: PubMed
    Score: 0.014
  13. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities. Stat Med. 2011 Jul 30; 30(17):2130-43.
    View in: PubMed
    Score: 0.013
  14. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010 Mar; 12(3):274-82.
    View in: PubMed
    Score: 0.012
  15. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat Med. 2023 Dec; 29(12):3067-3076.
    View in: PubMed
    Score: 0.008
  16. Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. Lancet Oncol. 2023 04; 24(4):e161-e171.
    View in: PubMed
    Score: 0.008
  17. Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. J Clin Oncol. 2022 08 10; 40(23):2539-2545.
    View in: PubMed
    Score: 0.007
  18. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J Clin Oncol. 2022 04 20; 40(12):1323-1334.
    View in: PubMed
    Score: 0.007
  19. Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol. 2021 10; 22(10):e456-e465.
    View in: PubMed
    Score: 0.007
  20. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021 07 01; 113(7):808-819.
    View in: PubMed
    Score: 0.007
  21. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer. Clin Cancer Res. 2021 10 15; 27(20):5628-5637.
    View in: PubMed
    Score: 0.007
  22. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. J Clin Oncol. 2020 12 10; 38(35):4184-4193.
    View in: PubMed
    Score: 0.006
  23. A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):189-195.
    View in: PubMed
    Score: 0.006
  24. The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias. Blood Cancer J. 2020 03 16; 10(3):39.
    View in: PubMed
    Score: 0.006
  25. Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era. Leuk Lymphoma. 2020 02; 61(2):298-308.
    View in: PubMed
    Score: 0.006
  26. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348.
    View in: PubMed
    Score: 0.006
  27. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). Cancer. 2019 10 01; 125(19):3378-3389.
    View in: PubMed
    Score: 0.006
  28. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019 07 20; 37(21):1790-1799.
    View in: PubMed
    Score: 0.006
  29. Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. Blood Cancer J. 2019 02 19; 9(3):20.
    View in: PubMed
    Score: 0.006
  30. Mass Cytometry Analysis Reveals that Specific Intratumoral CD4+ T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma. Cell Rep. 2019 02 19; 26(8):2178-2193.e3.
    View in: PubMed
    Score: 0.006
  31. Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. Blood Cancer J. 2018 10 10; 8(10):96.
    View in: PubMed
    Score: 0.006
  32. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat. 2018 01; 167(1):89-99.
    View in: PubMed
    Score: 0.005
  33. Comparison of confidence interval methods for an intra-class correlation coefficient (ICC). BMC Med Res Methodol. 2014 Nov 22; 14:121.
    View in: PubMed
    Score: 0.004
  34. Immunotherapy and radiation therapy: considerations for successfully combining radiation into the paradigm of immuno-oncology drug development. Radiat Res. 2014 Aug; 182(2):252-7.
    View in: PubMed
    Score: 0.004
  35. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013 Dec 18; 105(24):1897-906.
    View in: PubMed
    Score: 0.004
  36. Criteria for the use of omics-based predictors in clinical trials. Nature. 2013 Oct 17; 502(7471):317-20.
    View in: PubMed
    Score: 0.004
  37. Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med. 2013 Oct 17; 11:220.
    View in: PubMed
    Score: 0.004
  38. Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer. Ann Oncol. 2013 Aug; 24(8):2073-9.
    View in: PubMed
    Score: 0.004
  39. Randomized phase II trial designs with biomarkers. J Clin Oncol. 2012 Sep 10; 30(26):3304-9.
    View in: PubMed
    Score: 0.004
  40. Heparan sulfate sulfatase SULF2 regulates PDGFRa signaling and growth in human and mouse malignant glioma. J Clin Invest. 2012 Mar; 122(3):911-22.
    View in: PubMed
    Score: 0.003
  41. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011 Dec; 13(12):1331-8.
    View in: PubMed
    Score: 0.003
  42. Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy. J Neurooncol. 2012 Jan; 106(2):367-75.
    View in: PubMed
    Score: 0.003
  43. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett. 2011 Jul 28; 306(2):223-9.
    View in: PubMed
    Score: 0.003
  44. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011 Jul; 115(1):3-8.
    View in: PubMed
    Score: 0.003
  45. Identifying the needs of brain tumor patients and their caregivers. J Neurooncol. 2011 Sep; 104(3):737-44.
    View in: PubMed
    Score: 0.003
  46. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 2011 Apr; 13(4):384-92.
    View in: PubMed
    Score: 0.003
  47. Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme. Neuro Oncol. 2011 May; 13(5):546-57.
    View in: PubMed
    Score: 0.003
  48. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg. 2011 Jun; 114(6):1609-16.
    View in: PubMed
    Score: 0.003
  49. Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011 Jan; 13(1):119-31.
    View in: PubMed
    Score: 0.003
  50. Assessment of morbidity following resection of cingulate gyrus gliomas. Clinical article. J Neurosurg. 2011 Mar; 114(3):640-7.
    View in: PubMed
    Score: 0.003
  51. En bloc resection for primary and metastatic tumors of the spine: a systematic review of the literature. Neurosurgery. 2010 Aug; 67(2):435-44; discussion 444-5.
    View in: PubMed
    Score: 0.003
  52. Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Neuro Oncol. 2010 Nov; 12(11):1152-61.
    View in: PubMed
    Score: 0.003
  53. Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. J Neurosurg. 2011 Mar; 114(3):566-73.
    View in: PubMed
    Score: 0.003
  54. Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol. 2011 Jan; 101(2):267-77.
    View in: PubMed
    Score: 0.003
  55. Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. Neuro Oncol. 2010 Sep; 12(9):908-16.
    View in: PubMed
    Score: 0.003
  56. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol. 2010 Jun; 12(6):608-13.
    View in: PubMed
    Score: 0.003
  57. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 2010 Jan 15; 70(2):512-9.
    View in: PubMed
    Score: 0.003
  58. Insular glioma resection: assessment of patient morbidity, survival, and tumor progression. J Neurosurg. 2010 Jan; 112(1):1-9.
    View in: PubMed
    Score: 0.003
  59. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol. 2010 Mar; 97(1):33-40.
    View in: PubMed
    Score: 0.003
  60. Quality of life in low-grade glioma patients receiving temozolomide. Neuro Oncol. 2009 Feb; 11(1):59-68.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.